TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall Response Rate (ORR) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events, and serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue Oxygenation Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of subjects with renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with Cervical infection with HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Curing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bleeding Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plaque Control Record
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Schiff Air Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Basic Erosive Wear Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wong-Backer faces pain rating scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of vertigo attacks lasting more than 20 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long term safety assessed through adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Treated lesion progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eating Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dose of opioids used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roll-call absence prevalence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Self-reported absence prevalence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 2- and 7-day period prevalence of diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knowledge regarding nutrition and WASH
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude regarding nutrition and WASH
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Practices regarding nutrition and WASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Variability in Peak Inspiratory Flow (PIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Viral load change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody avidity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monosodium urate crystal volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WAT/TAB conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to microdevice placement and removal
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of risk of COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Variation of destination arrival between both transportation types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of sample temperature during transportation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of sample degradation after both transportation types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical findings of rickets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric measures in rickets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical signs of rickets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone healing assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of traumatic brain injury (TBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maternal systemic microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maternal systemic macrovascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maternal uteroplacental function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: alpha-amylase activity in salivary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood pressures (systolic and diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area of patients with opaque bubble layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in inflammatory cytokine profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in gut microbiome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline fecal calprotectin at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Symptoms assessed by Simple Clinical Colitis Activity Index (SCCAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McMonnies Dry Eye Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycemic Control (Hemoglobin A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Left Ventricular Myocardial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum Levels of anti-aSyn Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CSF Levels of anti-aSyn Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported pain severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with solicited administration site events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with solicited systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Fold Change in resistance to Doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lymphocyte populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of fasting glycemia level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the diagnostic confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the therapeutic plan for the patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total forearm work performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events of avatrombopag treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Failure rate of platelet recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Isometric Mid-Thigh Pull (IMTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wingate Anaerobic Test (WAnT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dual-energy X-ray absorptiometry, DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bench press test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractal scaling exponent (α) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensification of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from hour 0 to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of belzutifan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration (Tmax) of belzutifan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of Immunoglobulin (Ig) G Antibodies Specific to the AlpN Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Technical Skills Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-technical skills performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Family Environment Survey (FES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant ratings of group cohesion
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Participant ratings of acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in safety-related empowerment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pregnancy stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self rating Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression self rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in limb volume affected by lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic residual pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Caries arresting potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Remineralization efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Suicide Stroop Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Apnea hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of patients with adequate visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Board of Orthodontics (ABO) scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield rate of intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Received or prescribed ORS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Received or prescribed antibiotic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chemotherapy-induced peripheral neurotoxicity (CIPN) as assessed by Total Neuropathy Score (TNSn©)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in ability to concentrate, selective attention and processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of SARS-CoV-2 S protein antibody (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of SARS-CoV-2 neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Denver II Developmental Screening Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alberta infant motor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaCO2 in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SaO2 percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burst suppression monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oral mucositis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent completion of food
Endpoint domain: Resource use
Primary endpoint: Percent completion of ketone logs
Endpoint domain: Resource use
Primary endpoint: Incidents of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum intensity of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Teratogenic effects on the fetus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incremental cost-to-utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Teaching Material Motivation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Student Interest Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude Scale Towards Learning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Class participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Ejaculatory function as assessed by the Male Sexual Health Questionnaire - Ejaculatory function domain (EJ-MSHQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Sexual function as assessed by the International Index of Erectile Function Questionnaire (IIEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients obtaining full core omic characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of advanced liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bladder sensitivity to filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Volume voided at maximum tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urine PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of detected impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White matter hyperintensity of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with confirmed or suggested TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Brain Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Event free survival (EFS) at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Analgesic opioids consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ventilator-induced lung injury (barotrauma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Trial adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: objective/histologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Improvement of Androgenetic Alopecia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose (MTD) of liposomal irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-admission rates post Revascularisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MACE post Revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: red cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual Infusion Phlebitis Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of blinks during the 10-minute video
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of palpebral fissure of both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (Cmax) of TCZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from Days 0-28 (AUC days 0-28) of TCZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (CL) of TCZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful clinical infection resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: False-negative rate (FNR) of TAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of neuromuscular blockade recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful recording of impedance and magnetic localization information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rapid-3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norepinephrine dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic Spine Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: New York Posture Rating Chart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: World Health Organization Quality of Life Assessment (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Renal function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Numerical Rating Scale Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' symptoms following resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early radiation-induced toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerate dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Emergent Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Respiratory Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evaluation of Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posture Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ethinylestradiol plasma concentration time curve (AUC0-24h,EE,SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the levonorgestrel plasma concentration time curve (AUC0-24h,LN,SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estrogen Receptor Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of new surgical technique TAD using Magseed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Geometric mean titer of neutralizing antibody to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained clinical resolution of symptoms of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fascia plane mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Linezolid-induced thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acquisition Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum levels of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Students Who Attrite From the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Student Treatment Satisfaction as Measured by the Client Satisfaction Questionnaire (CSQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Adherence as Measured by DBT (Dialectical Behavior Therapy) Adherence Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes